Manufacturer of Controlled Substances; Notice of Application, 5829 [2011-2237]
Download as PDF
5829
Federal Register / Vol. 76, No. 22 / Wednesday, February 2, 2011 / Notices
Dated: January 18, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Dated: January 18, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2011–2284 Filed 2–1–11; 8:45 am]
[FR Doc. 2011–2288 Filed 2–1–11; 8:45 am]
BILLING CODE 4410–09–P
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on May 25, 2010,
AMRI Rensselaer, Inc., 33 Riverside
Avenue, Rensselaer, New York 12144,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the following basic
classes of controlled substances:
Drug
Schedule
srobinson on DSKHWCL6B1PROD with NOTICES
Marihuana (7360) .........................
Tetrahydrocannabinols (7370) .....
Amphetamine (1100) ....................
Lisdexamfetamine (1205) .............
Methylphenidate (1724) ................
Pentobarbital (2270) .....................
Meperidine (9230) ........................
Fentanyl (9801) ............................
I
I
II
II
II
II
II
II
16:00 Feb 01, 2011
Jkt 223001
Schedule
Drug
The company plans to manufacture
bulk controlled substances for use in
product development and for
distribution to its customers.
In reference to drug code 7360
(Marihuana), the company plans to bulk
manufacture cannabidiol as a synthetic
intermediate. This controlled substance
will be further synthesized to bulk
manufacture a synthetic THC (7370). No
other activity for this drug code is
authorized for this registration.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than April 4, 2011.
VerDate Mar<15>2010
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on November 24,
2010, Sigma Aldrich Research
Biochemicals, Inc., 1–3 Strathmore
Road, Natick, Massachusetts 01760–
2447, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the following classes of
controlled substances:
Cathinone (1235) ...........................
Methcathinone (1237) ....................
Aminorex (1585) .............................
Alpha-ethyltryptamine (7249) .........
Lysergic acid diethylamide (7315)
Tetrahydrocannabinols (7370) .......
4-Bromo-2,5dimethoxyamphetamine (7391).
4-Bromo-2,5dimethoxyphenethylamine (7392).
2,5-Dimethoxyamphetamine (7396)
3,4-Methylenedioxyamphetamine
(7400).
N-Hydroxy-3,4methylenedioxyamphetamine
(7402).
3,4-Methylenedioxy-Nethylamphetamine (7404).
3,4Methylenedioxymethamphetamine (MDMA) (7405).
Psilocybin (7437) ............................
5-Methoxy-N,Ndiisopropyltryptamine (7439).
1-[1-(2Thienyl)cyclohexyl]piperidine
(TCP) (7470).
N-Benzylpiperazine (BZP) (7493) ..
Heroin (9200) .................................
Normorphine (9313) .......................
Amphetamine (1100) ......................
Methamphetamine (1105) ..............
Nabilone (7379) ..............................
1-Phenylcyclohexylamine (7460) ...
Phencyclidine (7471) ......................
Cocaine (9041) ...............................
Codeine (9050) ..............................
Diprenorphine (9058) .....................
Ecgonine (9180) .............................
Levomethorphan (9210) .................
Levorphanol (9220) ........................
PO 00000
Frm 00052
Fmt 4703
Sfmt 4703
I
I
I
I
I
I
I
Drug
Meperidine (9230) ..........................
Metazocine (9240) .........................
Methadone (9250) ..........................
Morphine (9300) .............................
Thebaine (9333) .............................
Levo-alphacetylmethadol (9648) ....
Remifentanil (9739) ........................
Carfentanil (9743) ..........................
Fentanyl (9801) ..............................
Schedule
II
II
II
II
II
II
II
II
II
The company plans to manufacture
reference standards.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than April 4, 2011.
Dated: January 18, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2011–2237 Filed 2–1–11; 8:45 am]
BILLING CODE 4410–09–P
I
DEPARTMENT OF JUSTICE
I
I
Drug Enforcement Administration
I
Manufacturer of Controlled
Substances; Notice of Registration
I
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
By Notice dated August 3, 2010, and
published in the Federal Register on
September 1, 2010, 75 FR 53719,
Cambridge Isotope Lab, 50 Frontage
Road, Andover, Massachusetts 01810,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of Morphine (9300), a
basic class of controlled substance listed
in schedule II.
The company plans to utilize small
quantities of the listed controlled
substance in the preparation of
analytical standards.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Cambridge Isotope Lab to manufacture
the listed basic class of controlled
substance is consistent with the public
interest at this time. DEA has
E:\FR\FM\02FEN1.SGM
02FEN1
Agencies
[Federal Register Volume 76, Number 22 (Wednesday, February 2, 2011)]
[Notices]
[Page 5829]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-2237]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Sec. 1301.33(a), Title 21 of the Code of Federal
Regulations (CFR), this is notice that on November 24, 2010, Sigma
Aldrich Research Biochemicals, Inc., 1-3 Strathmore Road, Natick,
Massachusetts 01760-2447, made application by renewal to the Drug
Enforcement Administration (DEA) to be registered as a bulk
manufacturer of the following classes of controlled substances:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Cathinone (1235)............................ I
Methcathinone (1237)........................ I
Aminorex (1585)............................. I
Alpha-ethyltryptamine (7249)................ I
Lysergic acid diethylamide (7315)........... I
Tetrahydrocannabinols (7370)................ I
4-Bromo-2,5-dimethoxyamphetamine (7391)..... I
4-Bromo-2,5-dimethoxyphenethylamine (7392).. I
2,5-Dimethoxyamphetamine (7396)............. I
3,4-Methylenedioxyamphetamine (7400)........ I
N-Hydroxy-3,4-methylenedioxyamphetamine I
(7402).
3,4-Methylenedioxy-N-ethylamphetamine (7404) I
3,4-Methylenedioxymethamphetamine (MDMA) I
(7405).
Psilocybin (7437)........................... I
5-Methoxy-N,N-diisopropyltryptamine (7439).. I
1-[1-(2-Thienyl)cyclohexyl]piperidine (TCP) I
(7470).
N-Benzylpiperazine (BZP) (7493)............. I
Heroin (9200)............................... I
Normorphine (9313).......................... I
Amphetamine (1100).......................... II
Methamphetamine (1105)...................... II
Nabilone (7379)............................. II
1-Phenylcyclohexylamine (7460).............. II
Phencyclidine (7471)........................ II
Cocaine (9041).............................. II
Codeine (9050).............................. II
Diprenorphine (9058)........................ II
Ecgonine (9180)............................. II
Levomethorphan (9210)....................... II
Levorphanol (9220).......................... II
Meperidine (9230)........................... II
Metazocine (9240)........................... II
Methadone (9250)............................ II
Morphine (9300)............................. II
Thebaine (9333)............................. II
Levo-alphacetylmethadol (9648).............. II
Remifentanil (9739)......................... II
Carfentanil (9743).......................... II
Fentanyl (9801)............................. II
------------------------------------------------------------------------
The company plans to manufacture reference standards.
Any other such applicant, and any person who is presently
registered with DEA to manufacture such substances, may file comments
or objections to the issuance of the proposed registration pursuant to
21 CFR 1301.33(a).
Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than April 4, 2011.
Dated: January 18, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2011-2237 Filed 2-1-11; 8:45 am]
BILLING CODE 4410-09-P